ArticleSignal transduction and targeted therapy2023
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04975932 (Efficacy and Safety of Transarterial Chemoembolization in Combination With Immune Checkpoint Inhibitors for Hepatocellular Carcinoma), which is not on this map. Cited by 214 papers, 11 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed, 11 pooled it
54.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Transarterial Chemoembolization in Combination With Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: a Real-world Study
Who cites it
214 citing papers in PubMed, 11 syntheses or guidelines pooled it, 266 citations in OpenAlex.
- The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to transarterial chemoembolisation for unresectable, non-metastatic hepatocellular carcinoma: a pooled analysis of four RCTs.Frontiers in medicine · 2026Pooled it
- Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.World journal of surgical oncology · 2025Pooled it
- Efficacy of prophylactic dexamethasone in reducing post-embolization syndrome following transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis.World journal of surgical oncology · 2025Pooled it
- The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM.Frontiers in immunology · 2025Pooled it
- Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis.Frontiers in immunology · 2025Pooled it
- Efficacy of TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.Hepatology international · 2024Pooled it
- Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.Frontiers in immunology · 2024Pooled it
- Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.Frontiers in immunology · 2024Pooled it
- Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.Signal transduction and targeted therapy · 2026Trial
- Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.Signal transduction and targeted therapy · 2025Trial
- Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.Journal of translational medicine · 2025Trial
- Correlation Between Treatment-Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma.Cancer medicine · 2025Trial
- Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria.Journal for immunotherapy of cancer · 2025Trial
- Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study.ImmunoTargets and therapy · 2025Trial
- Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study.Signal transduction and targeted therapy · 2024Trial
- Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions.Annals of medicine · 2026Review
154 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors at 20 institutions in 1 country.
Hai-Dong Zhu *Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Hai-Liang Li *Department of Minimally invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China.
Ming-Sheng Huang *Department of Interventional Radiology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China.
Wei-Zhu Yang *Department of Interventional Radiology, Union Hospital of Fujian Medical University, Fuzhou, 350001, China.
Guo-Wen Yin *Department of Interventional Radiology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, China.
Bin-Yan ZhongDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China.ORCID 0000-0001-9716-1211
Jun-Hui SunHepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Zhi-Cheng JinCenter of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.ORCID 0000-0002-6114-154X
Jian-Jian ChenCenter of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Nai-Jian GeDepartment of Interventional Radiology, Eastern Hospital of Hepatobiliary Surgery, Navy Medical University (Second Military Medical University), Shanghai, 200438, China.
Wen-Bin DingDepartment of Interventional Radiology, Nantong First People's Hospital, Nantong, 226001, China.
Wen-Hui LiDepartment of Interventional Radiology, Yancheng Third People's Hospital, Yancheng, 224008, China.
Jin-Hua HuangDepartment of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Wei MuDepartment of Vascular Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
Shan-Zhi GuDepartment of Interventional Radiology, Hunan Cancer Hospital, Changsha, 410031, China.
Jia-Ping LiDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Hui ZhaoDepartment of Interventional Radiology, The Hospital of Nantong University, Nantong, 226001, China.
Shu-Wei WenDepartment of Interventional Therapy, Shanxi Tumor Hospital, Taiyuan, 030001, China.
Yan-Ming LeiDepartment of Interventional Radiology, Tibet Autonomous Region People's Hospital, Lhasa, 850000, China.
Yu-Sheng SongDepartment of Interventional Radiology, Ganzhou People's Hospital, Ganzhou, 341000, China.
Chun-Wang YuanCenter of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Wei-Dong WangDepartment of Interventional Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, 214023, China.
Ming HuangDepartment of Minimally Invasive Interventional Therapy, Yunnan Tumor Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China.
Wei ZhaoDepartment of Radiology, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Jian-Bing WuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Song WangDepartment of Interventional Radiology, Affiliated Hospital of Qingdao University, Qingdao, 266000, China.
Xu ZhuDepartment of Interventional Therapy, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, 100142, China.
Jian-Jun HanDepartment of Interventional Radiology, Affiliated Cancer Hospital of Shandong First Medical University, Jinan, 250117, China.
Wei-Xin RenInterventional Therapy Center, The first Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, China.
Zai-Ming LuDepartment of Radiology, Shengjing Hospital of China Medical University, Shenyang, 830011, China.
Wen-Ge XingDepartment of Interventional Oncology, Tianjin Medical University Cancer Hospital, Tianjin, 300060, China.
Yong FanDepartment of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Hai-Lan LinDepartment of Tumor Interventional Therapy, Fujian Cancer Hospital, Fuzhou, 350014, China.
Zi-Shu ZhangDepartment of Radiology, The Second Xiangya Hospital, Changsha, 410011, China.
Guo-Hui XuDepartment of Interventional Radiology, Sichuan Cancer Hospital and Institute, Chengdu, 610041, China.
Wen-Hao HuDepartment of Interventional Radiology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Qiang TuDepartment of Hepatobiliary Oncology Surgery, Department of Interventional Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, 330029, China.
Hong-Ying SuDepartment of Interventional Radiology, The First Hospital of China Medical University, Shenyang, 110001, China.
Chuan-Sheng ZhengDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 110001, China.
Yong ChenDepartment of Interventional Radiology, General hospital of Ningxia Medical University, Yinchuan, 110001, China.
Xu-Ya ZhaoDepartment of Interventional Radiology, Guizhou Cancer Hospital, Guiyang, 550000, China.
Zhu-Ting FangDepartment of Interventional Radiology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Qi WangDepartment of Interventional Radiology, Third Affiliated Hospital of Soochow University, Changzhou First Hospital, Changzhou, 213004, China.
Jin-Wei ZhaoDepartment of Interventional and Vascular Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, 213003, China.
Ai-Bing XuDepartment of Interventional Therapy, Nantong Tumor Hospital, Nantong, 226006, China.
Jian XuDepartment of Interventional Therapy, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210002, China.
Qing-Hua WuDepartment of Interventional Radiology, Affiliated Hospital of Jiangnan University, Wuxi, 214122, China.
Huan-Zhang NiuDepartment of Interventional Radiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Jian WangDepartment of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, 100034, China.
Feng DaiDepartment of Interventional Radiology, The Second Hospital of Nanjing, Nanjing, 210000, China.
Dui-Ping FengDepartment of Oncology and Vascular Intervention, First Hospital of Shanxi Medical University, Taiyuan, 030001, China.
Qing-Dong LiVascular and Interventional Department, Chongqing University Cancer Hospital, Chongqing, 400000, China.
Rong-Shu ShiDepartment of Interventional Radiology, The Affiliated Hospital of Zunyi Medical College, Zunyi, 563000, China.
Jia-Rui LiDepartment of Interventional Therapy, The First Hospital of Jilin University, Changchun, 130000, China.
Guang YangDepartment of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hai-Bin ShiDepartment of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Jian-Song JiDepartment of Radiology, Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, School of Medicine, Lishui Hospital of Zhejiang University, Lishui, 323000, China.
Yu-E LiuDepartment of Interventional Radiology, Shanxi Provincial People's Hospital, Taiyuan, 030012, China.
Zheng CaiDepartment of Interventional Medicine, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Po YangDepartment of Interventional & Vascular Surgery, The Fourth Hospital of Harbin Medical University, Harbin, 150001, China.
Yang ZhaoDepartment of Biostatistics, Nanjing Medical University, Nanjing, 211166, China.
Xiao-Li ZhuDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China. zhuxiaoli90@163.com.
Li-Gong LuZhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, China. luligong1969@126.com.
Gao-Jun TengCenter of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China. gjteng@seu.edu.cn.
CHANCE001 Investigators
Sun Yat-sen University · CNZhongda Hospital Southeast University · CNPeking University · CNFujian Medical University · CNNanchang University · CNShanxi Medical University · CNSoochow University · CNAffiliated Hospital of Zunyi Medical College · CNArmy Medical University · CNCapital Medical University · CNCentral South University · CNChangzhou No.2 People's Hospital · CNChina Medical University · CNChongqing University · CNFirst Affiliated Hospital of Henan University of Science and Technology · CNFirst Affiliated Hospital Zhejiang University · CNFirst Hospital of China Medical University · CNFujian Provincial Cancer Hospital · CNGanzhou People's Hospital · CNGuizhou Cancer Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations. In this nationwide, retrospective, cohort study, 826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT (combination group, n = 376) or TACE monotherapy (monotherapy group, n = 450) were included from January 2018 to May 2021. The primary endpoint was progression-free survival (PFS) according to modified RECIST. The secondary outcomes included overall survival (OS), objective response rate (ORR), and safety. We performed propensity score matching approaches to reduce bias between two groups. After matching, 228 pairs were included with a predominantly advanced disease population. Median PFS in combination group was 9.5 months (95% confidence interval [CI], 8.4-11.0) versus 8.0 months (95% CI, 6.6-9.5) (adjusted hazard ratio [HR], 0.70, P = 0.002). OS and ORR were also significantly higher in combination group (median OS, 19.2 [16.1-27.3] vs. 15.7 months [13.0-20.2]; adjusted HR, 0.63, P = 0.001; ORR, 60.1% vs. 32.0%; P < 0.001). Grade 3/4 adverse events were observed at a rate of 15.8% and 7.5% in combination and monotherapy groups, respectively. Our results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS, OS, and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice, with an acceptable safety profile.
Indexed as
Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsCohort StudiesHumansMolecular Targeted TherapyPhospholipase DRetrospective StudiesPhospholipase Dphospholipase D1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04975932ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.